5ohd

From Proteopedia

(Difference between revisions)

Revision as of 10:24, 14 June 2023

Putative inactive (dormant) dimeric state of GHR transmembrane domain

Structural highlights

5ohd is a 2 chain structure with sequence from Homo sapiens. Full experimental information is available from OCA. For a guided tour on the structure components use FirstGlance.
Resources:	FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Disease

GHR_HUMAN Defects in GHR are a cause of Laron syndrome (LARS) [MIM:262500. A severe form of growth hormone insensitivity characterized by growth impairment, short stature, dysfunctional growth hormone receptor, and failure to generate insulin-like growth factor I in response to growth hormone.^[1] ^[2] ^[3] ^[4] ^[5] ^[6] ^[7] ^[8] ^[9] ^[10] Defects in GHR may be a cause of idiopathic short stature autosomal (ISSA) [MIM:604271. Short stature is defined by a subnormal rate of growth.^[11]

Function

GHR_HUMAN Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity). The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling. Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.

Publication Abstract from PubMed

BACKGROUND: Prior studies of the human growth hormone receptor (GHR) revealed a distinct role of spatial rearrangements of its dimeric transmembrane domain in signal transduction across membrane. Detailed structural information obtained in the present study allowed elucidating the bases of such rearrangement and provided novel insights into receptor functioning. METHODS: We investigated the dimerization of recombinant TMD fragment GHR254-294 by means of high-resolution NMR in DPC micelles and molecular dynamics in explicit POPC membrane. RESULTS: We resolved two distinct dimeric structures of GHR TMD coexisting in membrane-mimicking micellar environment and providing left- and right-handed helix-helix association via different dimerization motifs. Based on the available mutagenesis data, the conformations correspond to the dormant and active receptor states and are distinguished by cis-trans isomerization of Phe-Pro(266) bond in the transmembrane helix entry. Molecular dynamic relaxations of the structures in lipid bilayer revealed the role of the proline residue in functionally significant rearrangements of the adjacent juxtamembrane region supporting alternation between protein-protein and protein-lipid interactions of this region that can be triggered by ligand binding. Also, the importance of juxtamembrane SS bonding for signal persistency, and somewhat unusual aspects of transmembrane region interaction with water molecules were demonstrated. CONCLUSIONS: Two alternative dimeric structures of GHR TMD attributed to dormant and active receptor states interchange via allosteric rearrangements of transmembrane helices and extracellular juxtamembrane regions that support coordination between protein-protein and protein-lipid interactions. GENERAL SIGNIFICANCE: This study provides a holistic vision of GHR signal transduction across the membrane emphasizing the role of protein-lipid interactions.

Structural basis of the signal transduction via transmembrane domain of the human growth hormone receptor.,Bocharov EV, Lesovoy DM, Bocharova OV, Urban AS, Pavlov KV, Volynsky PE, Efremov RG, Arseniev AS Biochim Biophys Acta. 2018 Mar 21;1862(6):1410-1420. doi:, 10.1016/j.bbagen.2018.03.022. PMID:29571748^[12]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

↑ Amselem S, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay MC, Goossens M. Laron dwarfism and mutations of the growth hormone-receptor gene. N Engl J Med. 1989 Oct 12;321(15):989-95. PMID:2779634
↑ Kou K, Lajara R, Rotwein P. Amino acid substitutions in the intracellular part of the growth hormone receptor in a patient with the Laron syndrome. J Clin Endocrinol Metab. 1993 Jan;76(1):54-9. PMID:8421103
↑ Amselem S, Duquesnoy P, Duriez B, Dastot F, Sobrier ML, Valleix S, Goossens M. Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome. Hum Mol Genet. 1993 Apr;2(4):355-9. PMID:8504296
↑ Edery M, Rozakis-Adcock M, Goujon L, Finidori J, Levi-Meyrueis C, Paly J, Djiane J, Postel-Vinay MC, Kelly PA. Lack of hormone binding in COS-7 cells expressing a mutated growth hormone receptor found in Laron dwarfism. J Clin Invest. 1993 Mar;91(3):838-44. PMID:8450064 doi:http://dx.doi.org/10.1172/JCI116304
↑ Duquesnoy P, Sobrier ML, Duriez B, Dastot F, Buchanan CR, Savage MO, Preece MA, Craescu CT, Blouquit Y, Goossens M, et al.. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. EMBO J. 1994 Mar 15;13(6):1386-95. PMID:8137822
↑ Sobrier ML, Dastot F, Duquesnoy P, Kandemir N, Yordam N, Goossens M, Amselem S. Nine novel growth hormone receptor gene mutations in patients with Laron syndrome. J Clin Endocrinol Metab. 1997 Feb;82(2):435-7. PMID:9024232
↑ Walker JL, Crock PA, Behncken SN, Rowlinson SW, Nicholson LM, Boulton TJ, Waters MJ. A novel mutation affecting the interdomain link region of the growth hormone receptor in a Vietnamese girl, and response to long-term treatment with recombinant human insulin-like growth factor-I and luteinizing hormone-releasing hormone analogue. J Clin Endocrinol Metab. 1998 Jul;83(7):2554-61. PMID:9661642
↑ Wojcik J, Berg MA, Esposito N, Geffner ME, Sakati N, Reiter EO, Dower S, Francke U, Postel-Vinay MC, Finidori J. Four contiguous amino acid substitutions, identified in patients with Laron syndrome, differently affect the binding affinity and intracellular trafficking of the growth hormone receptor. J Clin Endocrinol Metab. 1998 Dec;83(12):4481-9. PMID:9851797
↑ Enberg B, Luthman H, Segnestam K, Ritzen EM, Sundstrom M, Norstedt G. Characterisation of novel missense mutations in the GH receptor gene causing severe growth retardation. Eur J Endocrinol. 2000 Jul;143(1):71-6. PMID:10870033
↑ Jorge AA, Souza SC, Arnhold IJ, Mendonca BB. The first homozygous mutation (S226I) in the highly-conserved WSXWS-like motif of the GH receptor causing Laron syndrome: supression of GH secretion by GnRH analogue therapy not restored by dihydrotestosterone administration. Clin Endocrinol (Oxf). 2004 Jan;60(1):36-40. PMID:14678285
↑ Goddard AD, Covello R, Luoh SM, Clackson T, Attie KM, Gesundheit N, Rundle AC, Wells JA, Carlsson LM. Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med. 1995 Oct 26;333(17):1093-8. PMID:7565946
↑ Bocharov EV, Lesovoy DM, Bocharova OV, Urban AS, Pavlov KV, Volynsky PE, Efremov RG, Arseniev AS. Structural basis of the signal transduction via transmembrane domain of the human growth hormone receptor. Biochim Biophys Acta. 2018 Mar 21;1862(6):1410-1420. doi:, 10.1016/j.bbagen.2018.03.022. PMID:29571748 doi:http://dx.doi.org/10.1016/j.bbagen.2018.03.022

1 Structural highlights
2 Disease
3 Function
4 Publication Abstract from PubMed
5 References

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/5ohd"

@@ Line 1: / Line 1: @@
 ==Putative inactive (dormant) dimeric state of GHR transmembrane domain==
-<StructureSection load='5ohd' size='340' side='right'caption='[[5ohd]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''>
+<StructureSection load='5ohd' size='340' side='right'caption='[[5ohd]]' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>[[5ohd]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5OHD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5OHD FirstGlance]. <br>
+<table><tr><td colspan='2'>[[5ohd]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5OHD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5OHD FirstGlance]. <br>
-</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5oek|5oek]]</td></tr>
+</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5ohd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ohd OCA], [https://pdbe.org/5ohd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5ohd RCSB], [https://www.ebi.ac.uk/pdbsum/5ohd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5ohd ProSAT]</span></td></tr>
-<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">GHR ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
-<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5ohd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5ohd OCA], [http://pdbe.org/5ohd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5ohd RCSB], [http://www.ebi.ac.uk/pdbsum/5ohd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5ohd ProSAT]</span></td></tr>
 </table>
 == Disease ==
-[[http://www.uniprot.org/uniprot/GHR_HUMAN GHR_HUMAN]] Defects in GHR are a cause of Laron syndrome (LARS) [MIM:[http://omim.org/entry/262500 262500]]. A severe form of growth hormone insensitivity characterized by growth impairment, short stature, dysfunctional growth hormone receptor, and failure to generate insulin-like growth factor I in response to growth hormone.<ref>PMID:2779634</ref> <ref>PMID:8421103</ref> <ref>PMID:8504296</ref> <ref>PMID:8450064</ref> <ref>PMID:8137822</ref> <ref>PMID:9024232</ref> <ref>PMID:9661642</ref> <ref>PMID:9851797</ref> <ref>PMID:10870033</ref> <ref>PMID:14678285</ref>   Defects in GHR may be a cause of idiopathic short stature autosomal (ISSA) [MIM:[http://omim.org/entry/604271 604271]]. Short stature is defined by a subnormal rate of growth.<ref>PMID:7565946</ref>
+[https://www.uniprot.org/uniprot/GHR_HUMAN GHR_HUMAN] Defects in GHR are a cause of Laron syndrome (LARS) [MIM:[https://omim.org/entry/262500 262500]. A severe form of growth hormone insensitivity characterized by growth impairment, short stature, dysfunctional growth hormone receptor, and failure to generate insulin-like growth factor I in response to growth hormone.<ref>PMID:2779634</ref> <ref>PMID:8421103</ref> <ref>PMID:8504296</ref> <ref>PMID:8450064</ref> <ref>PMID:8137822</ref> <ref>PMID:9024232</ref> <ref>PMID:9661642</ref> <ref>PMID:9851797</ref> <ref>PMID:10870033</ref> <ref>PMID:14678285</ref>   Defects in GHR may be a cause of idiopathic short stature autosomal (ISSA) [MIM:[https://omim.org/entry/604271 604271]. Short stature is defined by a subnormal rate of growth.<ref>PMID:7565946</ref>
 == Function ==
-[[http://www.uniprot.org/uniprot/GHR_HUMAN GHR_HUMAN]] Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity).  The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.  Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.
+[https://www.uniprot.org/uniprot/GHR_HUMAN GHR_HUMAN] Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity).  The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.  Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.
 <div style="background-color:#fffaf0;">
 == Publication Abstract from PubMed ==
@@ Line 25: / Line 23: @@
 __TOC__
 </StructureSection>
-[[Category: Human]]
+[[Category: Homo sapiens]]
 [[Category: Large Structures]]
-[[Category: Arseniev, A S]]
+[[Category: Arseniev AS]]
-[[Category: Bocharov, E V]]
+[[Category: Bocharov EV]]
-[[Category: Bocharova, O V]]
+[[Category: Bocharova OV]]
-[[Category: Lesovoy, D M]]
+[[Category: Lesovoy DM]]
-[[Category: Urban, A S]]
+[[Category: Urban AS]]
-[[Category: Dimer]]
-[[Category: Ghr]]
-[[Category: Growth hormone receptor]]
-[[Category: Homodimer]]
-[[Category: Jak2 tyrosine kinase]]
-[[Category: Membrane protein]]
-[[Category: Receptor]]
-[[Category: Transmembrane domain]]

5ohd

From Proteopedia

Revision as of 10:24, 14 June 2023

Putative inactive (dormant) dimeric state of GHR transmembrane domain

Structural highlights

Disease

Function

Publication Abstract from PubMed

References

Contents

Proteopedia Page Contributors and Editors (what is this?)

Views

Personal tools

Navigation

Search

Toolbox